Vaxart (NASDAQ: VXRT) brought investors high hopes over the past several months. Imagine a vaccine without the jab: That's Vaxart's specialty. The clinical-stage biotech company is developing oral vaccines for a variety of viruses -- including SARS-CoV-2, the virus that causes COVID-19.
The company's shares soared more than 1,500% last year as Vaxart's investigational coronavirus vaccine made it through preclinical studies and began a human trial. Then, one specific element in the biotech company's phase 1 trial report disappointed investors, and the stock tumbled a massive 58% in one trading session on Feb. 3.
Now the question is about risk. How risky is it to invest in, or hold on to, Vaxart shares right now?
Source Fool.com